Grupo LALA announces dividend payment

PR Newswire

MEXICO CITY, May 19, 2021 /PRNewswire/ — Grupo LALA, S.A.B. de C.V., a Mexican company focused on the healthy food industry (“LALA”) (BMV: LALAB), today announced that the payment of an annual cash dividend in the amount of $ 0.6152 pesos per outstanding LALA share, representing the total LALA capital stock in circulation, was approved at the Company’s Ordinary General Shareholders’ Meeting (the “Meeting”) held on April 16, 2021. The dividend is payable in four installments of MXN $0.1538 each to holders of the Common Stock of record.

The first dividend payment referenced above will be made on May 26, 2021 in the amount of MXN $0.1538 for each share, representing the total LALA shares in circulation as of the payment date, upon the delivery of coupon No. 28.

In accordance with the Meeting’s resolution, the cash dividend will be taken from earnings generated by the Company since fiscal year 2014 and is therefore subject to a 10% income tax retention based on applicable tax regulations.

Regarding the share certificates deposited with the S.D. Indeval (Institución para el Depósito de Valores S.A. de C.V.), this dividend payment will be made through said Institution in accordance with the terms and conditions of the respective contracts entered into by LALA shareholders with their respective securities custodian.

About LALA:

Grupo LALA, a Mexican company focused on the healthy and nutritious food industry, has more than 70 years of experience in the production, innovation and marketing of milk, dairy products and beverages under the highest quality standards. LALA operates 29 production plants and 173 distribution centers in Mexico, Brazil, the United States and Central America, and is supported by more than 40,000 employees. LALA operates a fleet that exceeds 7,500 units for the distribution of its more than 600 products which reach more than 628,000 points of sale. LALA®, Nutri® and Vigor® stand out in their brand portfolio.

For more information visit: www.lala.com.mx

“Grupo LALA is listed on the Mexican Stock Exchange under the ticker “LALAB”

Cision View original content:http://www.prnewswire.com/news-releases/grupo-lala-announces-dividend-payment-301295434.html

SOURCE Grupo LALA, S.A.B. de C.V.

Northland Power Reports on the 2021 Annual and Special Meeting

TORONTO, May 19, 2021 (GLOBE NEWSWIRE) — Northland Power Inc. (“Northland” or the “Company”) (TSX: NPI) today announced the results of the election of Directors at its Annual and Special Meeting (“the Meeting”) held on May 19, 2021 in a virtual-only meeting format.

The total number of voting shares represented by shareholders present electronically and by proxy at the Meeting was 126,732,525, representing 62.54% of Northland’s outstanding voting shares.

The nine nominees proposed by Management for election as Directors, including the two new Directors, Kevin Glass and Helen Mallovy Hicks, were elected. Information on each of the Director Nominees is contained in Northland’s Management Information Circular dated April 14, 2021, which is available on the company’s website at www.northlandpower.com

The votes received were as follows:

Nominee Votes For Percent Withheld Percent
John W. Brace 123,200,266 97.64 % 2,975,886 2.36 %
Linda L. Bertoldi 126,040,320 99.89 % 135,832 0.11 %
Dr. Marie Bountrogianni 115,725,233 91.72 % 10,450,919 8.28 %
Lisa Colnett 120,806,417 95.74 % 5,369,735 4.26 %
Russell Goodman 123,884,343 98.18 % 2,291,809 1.82 %
Keith Halbert 125,511,335 99.47 % 664,817 0.53 %
Ian Pearce 116,628,539 92.43 % 9,547,613 7.57 %
Kevin Glass 125,547,078 99.50 % 629,074 0.50 %
Helen Mallovy Hicks 124,014,342 98.29 % 2,161,810 1.71 %

The Board of Directors accordingly fixed the number of Directors to be elected at nine and the election proceeded on that basis.

The Appointment of Ernst & Young LLP to serve as the independent auditors of Northland, and setting of their remuneration, until the next annual meeting was approved.   Votes received were as follows:

Votes For Percent Withheld Percent
117,629,627 92.82 % 9,102,898 7.18 %

The resolution to amend the Corporation’s articles to increase the permitted size of Board from the current range of three to nine directors to a range of three to twelve directors, and to permit the removal of all references to the Class A shares and Class B and C Convertible Shares was approved. Votes received were as follows:

Votes For Percent Against Percent
125,207,404 99.23 % 967,748 0.77 %

Northland’s approach to executive compensation was accepted. Votes received were as follows:

Votes For Percent Against Percent
123,341,126 97.75 % 2,835,025 2.25 %

ABOUT NORTHLAND POWER

Northland Power is a global power producer dedicated to helping the clean energy transition by producing electricity from clean renewable resources. Founded in 1987, Northland has a long history of developing, building, owning and operating clean and green power infrastructure assets and is a global leader in offshore wind. In addition, Northland owns and manages a diversified generation mix including onshore renewables and efficient natural gas energy, as well as supplying energy through a regulated utility.

Headquartered in Toronto, Canada, with global offices in eight countries, Northland owns or has an economic interest in
2.7
GW (net
2.3
GW) of operating generating capacity and a significant inventory of early to mid-stage development opportunities encompassing approximately 4 to 5 GW of potential capacity.

Publicly traded since 1997, Northland’s common shares, Series 1, Series 2 and Series 3 preferred shares trade on the Toronto Stock Exchange under the symbols NPI, NPI.PR.A, NPI.PR.B and NPI.PR.C, respectively.

For further information, please contact:

Wassem Khalil, Senior Director, Investor Relations & Strategy
+1 (647) 288-1019
[email protected]



Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society for Clinical Oncology

  • Updated results from phase I dose expansion in head and neck cancer showed durable signs of efficacy at a median follow up of 8.1 months, with an overall objective response rate of 82.5% and a complete response rate of 62.5%
  • Data from the expansion part of the study continue to support NBTXR3 as feasible and well-tolerated in highly vulnerable patients with high unmet needs and significant burden of disease
  • Updates to immunotherapy data that have supported NBTXR3 plus anti-PD-1 as a potential option to yield sustained immune response in patients with locally advanced or metastatic tumors, regardless of prior anti-PD-1 exposure, will be reported prior to the conference
  • Following ASCO, Nanobiotix will host an investor event on Friday, June 11, 2021 at 8am ET, to provide an in-depth review of the immunotherapy results with several key opinion leaders including study investigators (Register here)

PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)–
Regulatory News:

NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the upcoming presentation of updated results from the Company’s priority development pathways in head and neck cancer (head and neck squamous cell carcinoma; HNSCC) and in immunotherapy for advanced cancers at the 2021 Annual Meeting of the American Society for Clinical Oncology (ASCO). The Company will also present a poster with long-term safety analysis from its pivotal phase II/III study in soft tissue sarcoma.

“The data we will present at ASCO provide further support for the paradigm-shifting potential of NBTXR3 as a foundational solid tumor-agnostic and combination-agnostic cancer therapeutic,” said Laurent Levy, co-founder and chief executive officer of Nanobiotix. “We are excited to present both long-term safety data from our phase III soft tissue sarcoma study, along with updated safety and efficacy data from our second single-agent registration pathway in head and neck cancer. Moreover, we are particularly eager to present a growing body of data suggesting that after activation by radiotherapy, NBTXR3 may prime an immune response that could enhance the efficacy of immune checkpoint inhibitors as a first-line therapy, overcome resistance for refractory patients, and meaningfully expand the tumor types that respond to the class by transforming cold tumors into hot tumors.”

Local Control as a Single-Agent for Patients with Head and Neck Cancer

Abstract #6051: Phase I Dose Expansion Study of Functionalized Hafnium Oxide Nanoparticles (NBTXR3) in Cisplatin-Ineligible Locally Advanced HNSCC Patients

The number of elderly patients diagnosed with locally advanced HNSCC (LA-HNSCC) is increasing. While concurrent chemoradiation is the non-surgical standard of care, not all patients can tolerate platinum-based chemotherapy (e.g., cisplatin). The Nanobiotix phase I dose expansion study in patients with LA-HNSCC (Study 102) is evaluating a single dose of NBTXR3 at 22% of baseline tumor volume (the recommended phase II dose; RP2D). Primary endpoints of the study are objective response rate (ORR) and complete response rate (CRR) of the primary tumor. Study 102 is expected to recruit a total of 44 evaluable patients. To date, 52 total patients have been injected with NBTXR3 in the study overall, of which 40 have been evaluable.

Updated data presented at ASCO further support NBTXR3 administration, followed by activation with radiotherapy, as feasible and well-tolerated. Six (6) serious adverse events (SAEs) related to NBTXR3 were observed across five (5) patients. A total of ten (10) deaths related to adverse events were reported. Four (4) deaths related to radiotherapy were observed, along with one (1) death from sepsis that was investigator-assessed as possibly related to NBTXR3, radiotherapy, and cancer.

At a median follow up of 8.1 months, evaluable patients demonstrated a high primary tumor ORR of 82.5% and a 62.5% CRR. These results are consistent with those observed in the dose escalation part of the study and suggest durability of efficacy.

Nanobiotix plans to launch a pivotal phase III global registration trial evaluating NBTXR3 as a single-agent activated by radiotherapy for patients with LA-HNSCC in 2021.

Priming Immune Response and Immunotherapy Combination Across Oncology

Abstract #2590: A Phase I Study of NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy

Abstract #2591: Overcoming Resistance to Anti-PD-1 with Tumor-Agnostic NBTXR3: From Bench to Bedside

Cancer immunotherapies such as anti-PD-1 have shown promising clinical outcomes over the past two decades and are often used to treat advanced cancers once other therapies have reached the end of their effectiveness. However, across tumor indications, the significant majority of patients (80-85% according to published data) receive only a temporary benefit from anti-PD-1—or no benefit at all—as they either develop resistance to the therapy over time or are non-responsive to treatment altogether.

Previously reported data from the Company’s phase I immunotherapy study in advanced cancers (Study 1100) and its preclinical collaboration with The University of Texas MD Anderson Cancer Center support NBTXR3 activated by radiotherapy as a potential primer of immune response. These data suggest that when combined with anti-PD-1, NBTXR3 could contribute to tumor regression in patients with advanced and metastatic tumors regardless of the patient’s prior exposure to anti-PD-1.

Nanobiotix will provide an update on Study 1100 with additional patients and further follow up prior to the conference (abstract #2590). The Company will also present a compilation of preclinical and clinical data supporting NBTXR3 as a potentially tumor-agnostic, therapeutic combination-agnostic agent that could overcome resistance to immune checkpoint inhibitors and increase response rates across tumor indications (abstract #2591).

Local Control as a Single-Agent for Patients with Soft Tissue Sarcoma

Abstract #11544: Long-Term Evaluation of the Novel Radioenhancer NBTXR3 plus Radiotherapy in Patients with Locally Advanced Soft Tissue Sarcoma Treated in the Phase III Act.in.Sarc Trial

A long-term safety analysis following the Nanobiotix phase II/III pivotal study evaluating NBTXR3 as a single-agent activated by radiotherapy in patients with locally advanced soft tissue sarcoma (STS) did not observe a negative impact on patient quality of life and long-term morbidity. The long-term safety profile of NBTXR3, together with its efficacy data, further supported a favorable benefit-risk ratio for patients with STS. The analysis highlighted potential for future indications, including non-resectable sarcoma, pediatric tumors, and re-irradiation.

Nanobiotix Investor Event

Nanobiotix will host a virtual investor event featuring several key opinion leaders, including study investigators, after the ASCO Annual Meeting on Friday, June 11, 2021 at 8 am ET. The discussion will expand on the new immunotherapy results from Study 1100 that will be reported prior to ASCO, providing additional detail and clinical perspective, following the ASCO presentation. Register here.

***

About NBTXR3

NBTXR3 is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy. The product candidate’s physical mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy, subsequently triggering adaptive immune response and long-term anti-cancer memory. Given the physical MoA, Nanobiotix believes that NBTXR3 could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly immune checkpoint inhibitors.

NBTXR3 is being evaluated in locally advanced head and neck squamous cell carcinoma (HNSCC) as the primary development pathway. The company-sponsored phase I dose escalation and dose expansion study has produced favorable safety data and early signs of efficacy; and a phase III global registrational study is planned to launch in 2021. In February 2020, the United States Food and Drug Administration granted regulatory Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced HNSCC who are not eligible for platinum-based chemotherapy—the same population being evaluated in the planned phase III study.

Nanobiotix has also prioritized an Immuno-Oncology development program—beginning with a Company-sponsored phase I clinical study evaluating NBTXR3 activated by radiotherapy in combination with anti-PD-1 checkpoint inhibitors for patients with locoregional recurrent or recurrent/metastatic HNSCC and lung or liver metastases from any primary cancer eligible for anti-PD-1 therapy.

Given the Company’s focus areas, and balanced against the scalable potential of NBTXR3, Nanobiotix has engaged in a strategic collaboration strategy with world class partners to expand development of the product candidate in parallel with its priority development pathways. Pursuant to this strategy, in 2019 Nanobiotix entered into a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to sponsor several phase I and phase II studies to evaluate NBTXR3 across tumor types and therapeutic combinations.

About NANOBIOTIX:

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The company also has subsidiaries in Cambridge, Massachusetts (United States), France, Spain, and Germany. Nanobiotix has been listed on Euronext: Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020.

Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system. The company’s resources are primarily devoted to the development of its lead product candidate–NBTXR3—which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under the brand name Hensify®.

For more information about Nanobiotix, visit us at www.nanobiotix.comor follow us on LinkedIn and Twitter

Disclaimer

This press release contains certain “forward-looking” statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “at this time,” “anticipate,” “believe,” “expect,” “intend,” “on track,” “plan,” “scheduled,” and “will,” or the negative of these and similar expressions. These forward-looking statements, which are based on our management’s current expectations and assumptions and on information currently available to management, include statements about the timing and progress of clinical trials, the timing of our presentation of data, the results of our preclinical and clinical studies and their potential implications,the development and commercialization of NBTXR3, and the execution of the Company’s development and commercialization strategy. Such forward-looking statements are made in light of information currently available to us and based on assumptions that Nanobiotix considers to be reasonable. However, these forward-looking statements are subject to numerous risks and uncertainties, including with respect to the risk that subsequent studies and ongoing or future clinical trials may not generate favorable data notwithstanding positive preclinical or early clinical result and the risks associated with the evolving nature of the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to it. Furthermore, many other important factors, including those described in Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on April 7, 2021 under “Item 3.D. Risk Factors” and those set forth in the universal registration document of Nanobiotix filed with the French Financial Markets Authority (Autorité des marchés financiers) under number D.21-0272 on April 7, 2021 (a copy of which is available on www.nanobiotix.com), as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Nanobiotix

Communications Department

Brandon Owens

VP, Communications

+1 (617) 852-4835

[email protected]

Investor Relations Department

Kate McNeil

SVP, Investor Relations

+1 (609) 678-7388

[email protected]

Media Relations

France – Ulysse Communication

Pierre-Louis Germain

+ 33 (0) 6 64 79 97 51

[email protected]

US – Porter Novelli

Stefanie Tuck

+1 (917) 390-1394

[email protected]

KEYWORDS: Europe United States North America France Massachusetts

INDUSTRY KEYWORDS: Research Clinical Trials Biotechnology Other Health Health Pharmaceutical Other Science Science Oncology

MEDIA:

Logo
Logo

American Financial Group, Inc. Announces Intention to Declare Special Dividend

American Financial Group, Inc. Announces Intention to Declare Special Dividend

CINCINNATI–(BUSINESS WIRE)–
American Financial Group, Inc. (NYSE: AFG) announced today that it intends to pay a special, one-time cash dividend of $12.00 to $14.00 per share of American Financial Group Common Stock soon after the closing of the sale of its Annuity business to Massachusetts Mutual Life Insurance Company (MassMutual). The dividend is subject to AFG Board of Directors’ approval.

AFG expects to receive total after-tax cash sale proceeds of $3.4 billion. The sale is expected to close in the second quarter of 2021.

About American Financial Group, Inc.

American Financial Group is an insurance holding company, based in Cincinnati, Ohio. Through the operations of Great American Insurance Group, AFG is engaged primarily in property and casualty insurance, focusing on specialized commercial products for businesses, and in the sale of traditional fixed and fixed-indexed annuities in the retail, financial institutions, broker-dealer, and registered investment advisor markets. On January 27, 2021, AFG announced that it entered into a definitive agreement to sell its annuity business to Massachusetts Mutual Life Insurance Company. The sale is expected to close in the second quarter of 2021. Great American Insurance Group’s roots go back to 1872 with the founding of its flagship company, Great American Insurance Company.

Forward Looking Statements

This press release contains certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements in this press release not dealing with historical results are forward-looking and are based on estimates, assumptions and projections. Examples of such forward-looking statements include statements relating to: the Company’s expectations concerning market and other conditions and their effect on future premiums, revenues, earnings, investment activities and the amount and timing of share repurchases; recoverability of asset values; expected losses and the adequacy of reserves for asbestos, environmental pollution and mass tort claims; rate changes; and improved loss experience.

Actual results and/or financial condition could differ materially from those contained in or implied by such forward-looking statements for a variety of reasons including, but not limited to: that AFG may be unable to complete the proposed sale of its annuity business because, among other reasons, conditions to the closing of the proposed transaction may not be satisfied or waived, uncertainty as to the timing of completion of the proposed transaction, or failure to realize the anticipated benefits from the proposed transaction; changes in financial, political and economic conditions, including changes in interest and inflation rates, currency fluctuations and extended economic recessions or expansions in the U.S. and/or abroad; performance of securities markets, including the cost of equity index options; new legislation or declines in credit quality or credit ratings that could have a material impact on the valuation of securities in AFG’s investment portfolio; the availability of capital; changes in insurance law or regulation, including changes in statutory accounting rules, including modifications to capital requirements; the effects of the COVID-19 outbreak, including the effects on the international and national economy and credit markets, legislative or regulatory developments affecting the insurance industry, quarantines or other travel or health-related restrictions; changes in the legal environment affecting AFG or its customers; tax law and accounting changes; levels of natural catastrophes and severe weather, terrorist activities (including any nuclear, biological, chemical or radiological events), incidents of war or losses resulting from pandemics, civil unrest and other major losses; disruption caused by cyber-attacks or other technology breaches or failures by AFG or its business partners and service providers, which could negatively impact AFG’s business and/or expose AFG to litigation; development of insurance loss reserves and establishment of other reserves, particularly with respect to amounts associated with asbestos and environmental claims; availability of reinsurance and ability of reinsurers to pay their obligations; trends in persistency and mortality; competitive pressures; the ability to obtain adequate rates and policy terms; changes in AFG’s credit ratings or the financial strength ratings assigned by major ratings agencies to AFG’s operating subsidiaries; the impact of the conditions in the international financial markets and the global economy relating to AFG’s international operations; and other factors identified in AFG’s filings with the Securities and Exchange Commission.

The forward-looking statements herein are made only as of the date of this press release. The Company assumes no obligation to publicly update any forward-looking statements.

Diane P. Weidner, IRC

Vice President – Investor & Media Relations

(513) 369-5713

Websites:

www.AFGinc.com

www.GreatAmericanInsuranceGroup.com

KEYWORDS: United States North America Ohio

INDUSTRY KEYWORDS: Banking Professional Services Insurance Finance

MEDIA:

Logo
Logo

Ovintiv Closes Eagle Ford Asset Sale and Announces Early Redemption of Outstanding Notes

PR Newswire

Highlights:

  • Closed previously announced Eagle Ford asset sale
  • Issued notice to fully redeem outstanding 2022 notes in June of 2021
  • Announced intention to fully redeem outstanding 2021 notes at par in mid-August

DENVER, May 19, 2021 /PRNewswire/ – Ovintiv Inc. (NYSE: OVV) (TSX: OVV) today closed its previously announced Eagle Ford asset sale. The proceeds from this sale, combined with those recently received from the Duvernay asset sale, will be used for debt reduction.

In addition, the Company today announced that it has issued a notice to the trustee of its 5.75% notes due 2022 to redeem the entire $600 million aggregate principal amount. The outstanding 2022 notes will be redeemed, pursuant to their terms and conditions, on June 18, 2021. The Company also expects to redeem the entire $518 million aggregate principal amount of its outstanding 3.90% notes due 2021 at par in mid-August.

The combined redemption of the 2021 and 2022 notes represents approximately $1.1 billion of debt retirement for Ovintiv. Once redeemed, over $50 million of annualized interest expense will be removed from the Company’s cost structure. The Company’s next debt maturity is not until July of 2024.

“Today’s Eagle Ford asset sale continues our track record of delivery and allows us to meaningfully accelerate debt reduction,” said Ovintiv CEO, Doug Suttles. “With these proceeds, in combination with our strong free cash flow generation, we now expect to reach our debt target of $4.5 billion by the end of this year. Our priorities today are clear – reduce debt, maintain scale, drive efficiencies, and return cash to shareholders.”

BMO Capital Markets and Citigroup Global Markets, Inc. served as Ovintiv’s financial advisors and Davis Graham & Stubbs LLP served as Ovintiv’s legal advisor for the Eagle Ford transaction.

ADVISORY REGARDING FORWARD-LOOKING STATEMENTS – This news release is not a notice of redemption with respect to the 2021 notes or the 2022 notes. This news release contains certain forward-looking statements or information (collectively, “FLS”) within the meaning of applicable securities legislation, including the United States Private Securities Litigation Reform Act of 1995. FLS include: statements regarding the 2021 and 2022 notes, including timing and source of funds for the redemption thereof; and the Company’s ability to meet targets, including with respect to debt reduction. FLS involve assumptions, risks and uncertainties that may cause such statements not to occur or results to differ materially. These assumptions include: future commodity prices and differentials; and expectations and projections made in light of the Company’s historical experience and its perception of historical trends. Risks and uncertainties include: commodity price volatility and impact to the Company’s stock price and cash flows; impact of COVID-19 to the Company’s operations, including maintaining ordinary staffing levels, securing operational inputs and executing on portions of its business; counterparty and credit risk; impact of changes in credit rating and access to liquidity; changes in or interpretation of laws or regulations; and other risks and uncertainties as described in the Company’s Annual Report on Form 10- K, Quarterly Report on Form 10-Q and as described from time to time in its other periodic filings as filed on EDGAR and SEDAR. Although the Company believes such FLS are reasonable, there can be no assurance they will prove to be correct. The above assumptions, risks and uncertainties are not exhaustive. FLS are made as of the date hereof and, except as required by law, the Company undertakes no obligation to update or revise any FLS.

Further information on Ovintiv Inc. is available on the Company’s website, www.ovintiv.com, or by contacting:



Investor contact:


(888) 525-0304 



Media contact:


(403) 645-2252

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/ovintiv-closes-eagle-ford-asset-sale-and-announces-early-redemption-of-outstanding-notes-301295330.html

SOURCE Ovintiv Inc.

Gracell Biotechnologies to Present Updated Results of GC012F FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma at ASCO 2021 and EHA 2021

PR Newswire

SUZHOU, China and PALO ALTO, Calif., May 19, 2021/PRNewswire/ — Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, is presenting updated results of their first-in-human multicenter study of GC012F for the treatment of relapsed and/or refractory multiple myeloma, a FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T cell therapy currently in development for the treatment of multiple myeloma, at the 2021 American Society of Clinical Oncology (“ASCO”) Annual Meeting and the European Hematology Association 2021 (“EHA2021”) Congress.

GC012F is a BCMA/CD19 dual-targeting CAR-T cell therapy developed on Gracell’s proprietary FasTCAR next-day manufacturing technology platform and is being evaluated in a Phase 1 investigator-initiated trial study.


  • As of January 12, 2021
    ,
    the study had enrolled and treated 19 patients at three dose levels with the highest dose level of 3×105 cells per kg. Additional patients were treated since last update (reported at ASH 2020) in the highest dose level.

  • Early Overall Response Rate (ORR) shows a promising 94.7% (18/19) with all responses being VGPR or better (sCR), demonstrating fast, deep and durable responses in all dose levels.

  • 100% of the patients treated at the highest dose level (n=9) obtained MRD negative sCR.

  • 18 of the 19 patients (94.7%) treated were classified as high-risk according to mSMART 3.0 guidelines and patients had received a median of 5 prior lines of therapy.

  • 94.7% (18/19) of the patients were triple exposed to a PI, IMiD, and at least a third treatment modality, including anti-CD38 targeted therapy.

  • The safety profile of GC012F was consistent with previous findings with mostly low grade of cytokine release syndrome (CRS) (84% Grade 1/2, 11% (n=2) patients Grade 3). No Grade 4 or 5 CRS and no ICANS (immune effector cell-associated neurotoxicity) were observed in any of the 19 patients. Treatment-emergent adverse events (TEAEs) presented predominantly as cytopenias and AST increase. All TEAEs resolved with standard therapy.

  • Patients are continued to be followed for efficacy and safety.

“The longer-term follow-up and additional patients treated with GC012F confirm the previous findings presented at ASH 2020 and are an additional confirmation for the impressive safety and efficacy shown with our dual-targeting CAR-T therapy, including in high risk patients,” said Dr. Martina Sersch, MD, Chief Medical Officer of Gracell. “High-risk patients are difficult to treat. All patients in the highest dose level showed an initial 100% MRD negative sCR, and these deep responses were maintained at month six post-infusion after treatment with GC012F and beyond. These are very encouraging data and they hold a promise for multiple myeloma patients with high risk features and beyond, including those who have failed or are no longer responding to standard treatment options. We are planning to expand our program globally including earlier lines of therapy and are looking forward to sharing updates as we advance our programs.”

Details on the poster presentations are shown below:



2021 ASCO Annual Meeting


Abstract 8014:

Long-term follow-up results of a multicenter first-in-human study of the dual BCMA/CD19 targeted FasTCAR-T GC012F for patients with relapsed/refractory multiple myeloma


Poster Release Date:


June 4, 2021                           



EHA2021 Virtual Congress


Abstract EP962:

Long-term follow-up results of a multicenter first-in-human study of the dual BCMA/CD19 targeted FasTCAR-T GC012F for patients with relapsed/refractory multiple myeloma


Poster Release Date:


June 11, 2021


About Multiple Myeloma

Multiple myeloma (MM) is the third most common type of blood cancer in the United States, originating from plasma cells, a type of immune cell that is typically responsible for secreting antibodies to fight infection. Globally, approximately 160,000 patients are diagnosed with MM every year with over 32,000 expected to be diagnosed in the United States in 2020. In recent years, many advances have been made to treat MM, however, the disease is still considered incurable. Multiple myeloma patients with certain cytogenetic and other abnormalities are classified by the International Myeloma Working Group, or IMWG, and Mayo Stratification for Myeloma and Risk-Adapted Therapy, or mSMART, criteria as high-risk patients. They represent 20-30% of the overall MM patient population. High-risk patients have a much higher risk of early relapse and shorter progression free and overall survival. These patients are considered the most difficult to treat MM patients, typically with a poor prognosis.


About GC012F

GC012F is a FasTCAR-enabled dual-targeting CAR-T product candidate that is currently being studied in an ongoing investigator-initiated Phase 1 trial across multiple centers in China for the treatment of MM. GC012F tackles MM by simultaneously targeting both malignant plasma cells expressing BCMA and early progenitor cells expressing CD19 in order to drive fast, deep and durable responses in MM patients.


About FasTCAR

CAR-T cells manufactured on Gracell’s proprietary FasTCAR platform appear younger, less exhausted and show enhanced proliferation, persistence, bone marrow migration and tumor cell clearance activities as demonstrated in preclinical studies. With next day manufacturing, FasTCAR is able to significantly improve cell production efficiency which may result in meaningful cost savings, increasing the accessibility of cell therapies for cancer patients.


About Gracell

Gracell Biotechnologies Inc. (“Gracell”) is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit

www.gracellbio.com

.


Follow @GracellBio on


LinkedIn

.


Cautionary Noted Regarding Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing date of the offering. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the section entitled “Risk Factors” in Gracell’s most recent annual report on Form 20-F as well as discussions of potential risks, uncertainties, and other important factors in Gracell’s subsequent filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Gracell specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Readers should not rely upon the information on this page as current or accurate after its publication date.


Media contact



Marvin Tang




[email protected]


Investor contact




Gracie Tong




[email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/gracell-biotechnologies-to-present-updated-results-of-gc012f-fastcar-enabled-bcmacd19-dual-targeting-car-t-cell-therapy-for-relapsedrefractory-multiple-myeloma-at-asco-2021-and-eha-2021-301295236.html

SOURCE Gracell Biotechnologies Inc.

Exact Sciences Strengthens Evidence Supporting Cologuard® and Oncotype DX® Tests and Deep Oncology Pipeline with Multiple Data Presentations at ASCO 2021

PR Newswire

MADISON, Wis., May 19, 2021 /PRNewswire/ — Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced new data on its cancer tests and treatment guidance tools will be showcased in seven presentations and one e-abstract at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually June 4-8. Data presented will reinforce the value of the Oncotype DX® tests in informing personalized treatment decisions and highlight industry research from Thrive, an Exact Sciences company, outlining the need to incorporate a blood-based, multi-cancer screening test into routine clinical care.

Exact Sciences Strengthens Evidence Supporting Cologuard® and Oncotype DX® Tests w Multiple Data Presentations @ASCO ’21

“We’re thrilled to participate in ASCO, alongside our collaborators at leading academic and medical institutions,” said Kevin Conroy, chairman and CEO of Exact Sciences. “Exact Sciences is changing the way we detect and treat cancer. The data being presented demonstrate our commitment to providing earlier answers and life-changing treatment guidance to patients and physicians, while strengthening our current tests and accelerating the introduction of new, innovative diagnostics.”

Studies supporting Exact Sciences screening and earlier detection efforts consist of a Cologuard® (mt-sDNA) modeling study in collaboration with Mayo Clinic to assess the impact of sessile serrated polyps on predicted colorectal cancer outcomes with Cologuard or FIT screening1, and clinical research from Thrive that emphasizes the need for integrating a multi-cancer screening test into the standard of care2.

Data being presented on the Oncotype DX® test portfolio include a new analysis, based on first results from the independent RxPONDER study, that reinforce the cost-effectiveness of the Oncotype DX Breast Recurrence Score® test in node-positive early-stage breast cancer3; an oral presentation from the West German Study Group (WSG) on the prospective phase III ADAPT study which used the Oncotype DX test to stratify patients with early-stage breast cancer4; and results from a patient-specific meta-analysis of three validation studies of the Oncotype DX Colon Recurrence Score test5.

Also being presented are findings from City of Hope’s Center for Precision Medicine that emphasize a comprehensive sequencing approach to help guide cancer treatment and assess risk for cancer and non-cancer diseases, using Exact Sciences’ GEM ExTra® panel6, and early study results from PFS Genomics Inc., a development stage company founded by radiation oncologists, recently acquired by Exact Sciences. PFS Genomics has identified a gene expression signature, named Profile for the Omission of Local Adjuvant. Radiation (POLAR), to predict whether women with early-stage invasive breast cancer, treated with breast conserving surgery, are likely to benefit from radiotherapy7.

Following are the seven abstracts that have been accepted at the 2021 ASCO Annual Meeting. The on-demand materials, including posters, will be available in the ASCO Meeting Library, starting at 9:00AM EDT on June 4, 2021.

Impact of the Sessile Serrated Polyp Pathway on Predicted Colorectal Cancer Outcomes in the CRC-AIM Model
Authors: Kisiel, J., et al.
Session: Prevention, Risk Reduction, and Hereditary Cancer
Abstract Number: 10545

Cancer screening utilization in patients diagnosed with cancer types with and without recommended screening modalities 
Authors: Cohain, A., et al.
Session: Prevention, Risk Reduction, and Hereditary Cancer
Abstract Number: 10557

Utilizing commercial health insurance claims data to identify the impact of cancer screening and estimate the added benefit of a multi-cancer liquid biopsy ordered during routine physical exams
Authors: Cohain, A., Hathaway, C., et al.
Session: Publication Only: Prevention, Risk Reduction, and Hereditary Cancer
Abstract Number: e22516

Cost-effectiveness of Oncotype DX Breast Recurrence Score test in postmenopausal women with node-positive early breast cancer based on the RxPONDER trial
Authors: Berdunov, V., et al.
Session: Breast Cancer – Local/Regional/Adjuvant
Abstract Number: 534

Prognostic impact of Recurrence Score, endocrine response and clinical-pathological factors in high-risk luminal breast cancer: Results from the WSG-ADAPT HR+/HER2- chemotherapy trial
Authors: Gluz, O., et. al
Session: Breast Cancer – Local/Regional/Adjuvant
Abstract Number: 504; Oral presentation on June 6, 2021 at 8 AM EDT.

Discovery and validation of a genomic signature to identify women with early-stage invasive breast cancer who may safely omit adjuvant radiotherapy after breast-conserving surgery
Authors: Sjöström, M., et al.
Session: Breast Cancer – Local/Regional/Adjuvant
Abstract Number: 512

Patient-specific meta-analysis of 3 validation studies of the 12-gene Colon Cancer Recurrence Score Assay for recurrence risk assessment after surgery with or without 5FU and oxaliplatin.
Authors: Yothers, G., et al.
Session: Gastrointestinal Cancer – Colorectal and Anal
Abstract Number: 3599

Prospective genomic testing of unselected cancer patients yields insights about cancer susceptibility and non-cancer disease with therapeutic implications
Authors: Gray, S., et al
Session: Prevention, Risk Reduction, and Hereditary Cancer
Abstract Number: 10603

# # #

About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter answers to give people the clarity to take life-changing action, earlier. Building on the success of Cologuard® and Oncotype® tests, Exact Sciences is investing in its product pipeline to support patients throughout their cancer diagnosis and treatment. Exact Sciences unites visionary collaborators to help advance the fight against cancer. For more information, please visit the company’s website at  www.exactsciences.com, follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook.


NOTE: Oncotype, Oncotype DX, Oncotype DX Breast Recurrence Score, Oncotype DX Breast DCIS Score, Oncotype DX Genomic Prostate Score, Oncotype MAP Pan-Cancer Tissue, and Oncotype DX AR-V7 Nucleus Detect are trademarks or registered trademarks of Genomic Health, Inc. Exact Sciences and Cologuard are trademarks or registered trademarks of Exact Sciences Corporation. GEM ExTra is a registered trademark of Ashion Analytics, LLC, an Exact Sciences Company. All other trademarks and service marks are the property of their respective owners. 

Forward-Looking Statements
This news release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future.  These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially from those anticipated. You should not place undue reliance on forward-looking statements. There can be no assurance that we will be able to (i) realize the anticipated benefit from the acquisition of PFS Genomics or (ii) successfully develop or commercialize any products or services utilizing PFS Genomics’ technology. Risks and uncertainties that may affect our forward-looking statements are described in the Risk Factors sections of our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.


____________________


1 Kisiel, J., et al. Abstract #10545, ASCO 2021.


2 Cohain, A., et al. Abstracts #10557 & e22516, ASCO 2021.


3 Berdunov V. et al. Abstract #534, ASCO 2021.


4 Gluz, O., et. Al. Abstract #504, ASCO 2021.


5 Yothers, G., et al. Abstract #3599, ASCO 2021.


6 Gray, S., et al. Abstract #10603, ASCO 2021.


7 Sjöström, M., et al. Abstract #512, ASCO 2021.

 

Investors:

Media (U.S.):

Media (Canada, Europe, Asia, Latin America):

Megan Jones

Stephanie Spanos

Federico Maiardi

+1 608-535-8815

+1 608-556-4380

+41 79-138-1326


[email protected]


[email protected]


[email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/exact-sciences-strengthens-evidence-supporting-cologuard-and-oncotype-dx-tests-and-deep-oncology-pipeline-with-multiple-data-presentations-at-asco-2021-301295421.html

SOURCE EXACT SCIENCES CORP

Extended Stay America Files Investor Presentation in Support of Transaction with Blackstone and Starwood Capital

Urges Shareholders to Vote on June 8 “FOR” the Sale on the WHITE Company Proxy Card

CHARLOTTE, N.C., May 19, 2021 (GLOBE NEWSWIRE) — Extended Stay America, Inc. (“ESA”) and its paired-share REIT, ESH Hospitality, Inc. (“ESH” and, together with ESA, “Extended Stay” or the “Company”) (NASDAQ: STAY) today filed an investor presentation with the Securities and Exchange Commission highlighting the immediate and compelling value the Company’s transaction with Blackstone and Starwood Capital will deliver to shareholders. The Special Meetings of Shareholders are scheduled for June 8, 2021.

The presentation emphasizes the fact that the $19.50 per share all-cash transaction provides compelling value and captures the future upside inherent in the Company’s strategic plan. It also highlights four key points that investors should consider before they vote.

Right Timing

  • Unique extended stay model drove resilience during pandemic and significant sector outperformance
  • Pre-announcement stock price at multi-year high already factoring in post-pandemic recovery and recent strategic initiatives, providing attractive baseline price for sale transaction

Right Price

  • 50%+ premium to pre pandemic share price provides immediate and compelling value to shareholders; an implied premium that has only expanded since the transaction announcement, with lodging stocks selling off 9%
  • Implied transaction multiple of 15.6x trailing 2020 EBITDA, 13.0x forward 2021E EBITDA and 11.0x pro-forma 2019 EBITDA, compared to STAY’s one-year pre-COVID average multiple of 9.1x EBITDA

Right Process

  • Boards fully committed to maximizing shareholder value having explored numerous alternatives over multiple years, including OpCo / PropCo and a whole company sale
  • Thorough market review over several years produced only Blackstone and Starwood as interested buyers, with no other buyers emerging since announcement
  • Rigorous negotiations over 2 months resulting in 5 price bumps, overseen by fully engaged and transparent Boards of directors

Right Transaction

  • Culmination of thorough, multi-year processes to explore value-enhancing alternatives
  • Supported and endorsed by Management, including the CEO, Bruce Haase
  • Superior to value implied by successful continued execution of business plan on a time and risk-adjusted basis

The presentation also highlights Tarsadia’s selective recollection of interactions with STAY, its misinformed perspective on relevant valuation benchmarks, and its value-destructive alternatives, including its ill-conceived OpCo / PropCo structure and levered share repurchases.

A copy of the full presentation can be found at: https://www.aboutstay.com/static-files/2d16fb4e-7bb1-4938-88f7-4012bee84c58.

Extended Stay shareholders are reminded that their vote is extremely important, no matter how many shares they own. Shareholders should vote “FOR” the proposal on the WHITE proxy card to approve the transaction and secure the certain, immediate and compelling value of $19.50 per paired share in cash.

About the Company

Extended Stay America, Inc. (“ESA”) and its brand Extended Stay America® is the leading brand in the mid-priced extended stay segment in the U.S. with 652 hotels. ESA’s subsidiary, ESH Hospitality, Inc., is the largest lodging REIT in North America by unit and room count, with 564 hotels and approximately 62,500 rooms in the U.S. ESA also franchises an additional 88 Extended Stay America® hotels. Visit www.esa.com for more information.

Contacts:

Media:

[email protected] or [email protected]

Investors:

Rob Ballew
[email protected]
(980) 345-1546

Additional Information and Where to Find It

This communication may be deemed to be solicitation material in respect of the proposed acquisition of Extended Stay America, Inc. and ESH Hospitality, Inc. (together, the “Companies”) by a joint venture of Blackstone Real Estate Partners and Starwood Capital Group. In connection with the proposed transaction, the Companies filed with the Securities and Exchange Commission (“SEC”) on April 26, 2021 a definitive joint proxy statement and has or will furnish the definitive joint proxy statement to the stockholders of the Companies. STOCKHOLDERS OF THE COMPANIES ARE ADVISED TO READ THE DEFINITIVE JOINT PROXY STATEMENT (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS THERETO) BECAUSE IT CONTAINS IMPORTANT INFORMATION. Investors may obtain a free copy of the definitive joint proxy statement and other relevant documents filed by the Companies with the SEC at the SEC’s Web site at http://www.sec.gov. The definitive joint proxy statement and such other documents filed with the SEC may also be obtained for free from the Investor Relations section of the Companies’ web site (https://www.aboutstay.com/investor-relations) or by directing a request to the Companies at [email protected].

Forward-Looking Statements

Certain statements contained in this document constitute “forward-looking statements” within the meaning of the federal securities laws. All statements other than statements of historical facts included in this document may be forward-looking, including statements regarding, among other things, the Companies’ ability to meet their debt service obligations, future capital expenditures (including future acquisitions and hotel renovation programs), their distribution policies, their development, growth and franchise opportunities, anticipated benefits or use of proceeds from dispositions, their plans, objectives, goals, beliefs, business strategies, business conditions, results of operations, financial position and business outlook, business trends and future events, including the COVID-19 pandemic, its effects on the foregoing, government actions taken in response to the COVID-19 pandemic and actions that the Companies have taken or plan to take in response to the pandemic and such effects. When used in this document, the words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “will,” “look forward to” and variations of such words or similar expressions are intended to identify forward-looking statements. The forward-looking statements are not historical facts, and are based upon the Companies’ current expectations, beliefs, estimates and projections, and various assumptions, many of which, by their nature, are inherently uncertain and beyond their control. There can be no assurance that management’s expectations, beliefs, estimates and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements.

There are a number of risks, uncertainties and other important factors, many of which are beyond the Companies’ control, that could cause their actual results to differ materially from the forward-looking statements contained in this communication. The potential risks and uncertainties include, among others, the possibility that Extended Stay America, Inc. may be unable to obtain required stockholder approvals or that other conditions to closing the proposed mergers may not be satisfied, such that the proposed mergers will not close or that the closing may be delayed; general economic conditions; the proposed mergers may involve unexpected costs, liabilities or delays; risks that the transaction disrupts current plans and operations of the Companies; the outcome of any legal proceedings related to the proposed mergers; and the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement. For more details on these and other potential risks and uncertainties, please refer to the definitive joint proxy statement and the documents that the Companies file with the SEC. All forward-looking statements speak only as of the date of this communication or, in the case of any document incorporated by reference, the date of that document. The Companies are under no duty to update any of the forward-looking statements after the date of this document to conform to actual results, except as required by applicable law.



BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BERKELEY, Calif. and VANCOUVER, British Columbia, May 19, 2021 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the “Shareholders“) for the years ended July 31, 2019 and July 31, 2020 held on May 18, 2021 (the “Meeting“). A total of 1,685,180 common shares of the Company (the “Common Shares“) were voted, representing 22.36% of the Company’s issued and outstanding Common Shares. At the Meeting, the Shareholders overwhelmingly voted in favour of all proposed resolutions that consisted of the following:

  1. The number of directors set at six;
  2. Election of Dr. William V. Williams, Mr. Jamieson Bondarenko, Dr. Charles Wiseman, Dr. Rebecca Taub, Mr. Vaughn C. Embro-Pantalony, and Mr. Martin Schmieg as directors of the Company;
  3. Appointment of MNP LLP as auditors of the Company for the ensuing year and authorizing the directors to fix their remuneration;
  4. Renewal of the Company’s stock option plan;
  5. Ratification of the number of directors set at six for the prior year ended July 31, 2019;
  6. Ratification of the election of Dr. William V. Williams, Mr. Jamieson Bondarenko, Mr. Richard Berman, Mr. Vaughn C. Embro-Pantalony, Dr. Rebecca Taub, and Dr. Charles Wiseman as directors of the Company for the prior year ended July 31, 2019;
  7. Ratification of the appointment of MNP LLP as the auditors of the Company for the prior year ended July 31, 2019 and ratifying the directors authorization to fix their remuneration;
  8. Ratification of the Company’s stock option plan for the prior year ended July 31, 2019; and
  9. Ratification of holding the Company’s annual general and special meeting for the year ended July 31, 2019 on May 18, 2021.

Having received Shareholder approval, the Company’s stock option plan remains subject to approval from the TSX Venture Exchange. The formal report on voting results with respect to all matters voted upon during the Meeting will be filed on the Company’s SEDAR profile at www.sedar.com.

About BriaCell

BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.

For additional information on BriaCell, please visit: https://briacell.com/.

Cautionary Note Regarding Forward-Looking Information

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s SEC filings. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

For further information, please contact:

Company Contact:

William V. Williams, MD
President & CEO
1-888-485-6340
[email protected]

Media Relations:

Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
[email protected]

Investor Relations Contact:

CORE IR
[email protected]



Star Bulk Carriers Corp. Reports Net Profit of $35.8 Million for the First Quarter of 2021 and Declares Quarterly Dividend of $0.30 Per Share

ATHENS, Greece, May 19, 2021 (GLOBE NEWSWIRE) — Star Bulk Carriers Corp. (the “Company” or “Star Bulk”) (Nasdaq: SBLK), a global shipping company focusing on the transportation of dry bulk cargoes, today announced its unaudited financial and operating results for the first quarter of 2021. Unless otherwise indicated or unless the context requires otherwise, all references in this press release to “we,” “us,” “our,” or similar references, mean Star Bulk Carriers Corp. and, where applicable, its consolidated subsidiaries.


Financial Highlights

(Expressed in thousands of U.S. dollars,
except for daily rates and per share data)
First quarter
2021
First quarter
2020
Voyage Revenues $ 200,467 $ 160,862  
Net income/(loss) $ 35,763 $ 2,755  
Adjusted Net income / (loss) (1) $ 35,744 $ (22,251 )
Net cash provided by operating activities $ 79,176 $ 32,097  
EBITDA (2) $ 84,499 $ 57,596  
Adjusted EBITDA (2) $ 84,667 $ 32,565  
Earnings / (loss) per share basic and diluted $ 0.36 $ 0.03  
Adjusted earnings / (loss) per share basic and diluted (1) $ 0.36 $ (0.23 )
Average Number of Vessels   119.3   116.0  
TCE Revenues (3) $ 156,394 $ 99,836  
Daily Time Charter Equivalent Rate (“TCE”) (3) $ 15,461 $ 10,949  
Average daily OPEX per vessel (4) $ 4,410 $ 4,047  
Average daily OPEX per vessel (excl. non recurring expenses) (4) $ 4,251 $ 4,047  
Average daily Net Cash G&A expenses per vessel (5) $ 1,087 $ 1,064  

(1)  Adjusted Net income / (loss) and Adjusted earnings / (loss) per share basic and diluted are non-GAAP measures. Please see the table at the end of this release for a reconciliation to Net income / (loss), which is the most directly comparable financial measure calculated and presented in accordance with U.S. GAAP, as well as for the definition of each measure.
(2)  EBITDA and Adjusted EBITDA are non-GAAP measures. Please see the table at the end of this release for a reconciliation of EBITDA and Adjusted EBITDA to Net Cash Provided by / (Used in) Operating Activities, which is the most directly comparable financial measure calculated and presented in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) as well as for the definition of each measure. To derive Adjusted EBITDA from EBITDA, we exclude non-cash gains / (losses).
(3)  Daily Time Charter Equivalent Rate (“TCE”) and TCE Revenues are non-GAAP measures. Please see the table at the end of this release for a reconciliation to Voyage Revenues, which is the most directly comparable financial measure calculated and presented in accordance with U.S. GAAP, as well as for the definition of each measure.
(4)  Average daily OPEX per vessel is calculated by dividing vessel operating expenses by Ownership days. Average daily OPEX per vessel (which excludes non recurring expenses) is calculated by dividing vessel operating expenses minus any non-recurring items (such as, increased costs due to the COVID-19 pandemic or pre-delivery expenses for each vessel at acquisition, if any) by Ownership days. In the future we may incur expenses that are the same as or similar to some of the adjustments.
(5)  Average daily Net Cash G&A expenses per vessel is calculated by (1) deducting the Management fee Income (if any), from, and (2) adding the Management fee expense to, the General and Administrative expenses (net of stock-based compensation expense and other non-cash charges) and (3) then dividing the result by the sum of Ownership days and Charter-in days. Please see the table at the end of this release for a reconciliation to General and administrative expenses, which is the most directly comparable financial measure calculated and presented in accordance with U.S. GAAP.

Petros Pappas, Chief Executive Officer of Star Bulk, commented:

“Star Bulk reported a strong first quarter of 2021, earning net income of $35.8 million, on TCE Revenues of $156.4 million, with daily TCE per vessel for the fleet increasing to $15,461. The majority of the fleet remains exposed to the spot market for Q3 and following, with current forward coverage at $21,168 for 82% of available days in Q2.

The Board of Directors has amended the Company’s dividend policy to substantially increase return of capital to our shareholders. As a result, the Company will be paying a dividend for Q1 of $0.30 / share for the first quarter.

Over the past months we have continued increasing our fleet with the acquisition of twelve vessels, on average younger than our current fleet, nine of which were delivered within Q1. We expect to take delivery of the remaining three vessels during Q2.

Our outlook for the market remains positive due to the reopening of the global economy and consequent increased demand across all key dry bulk commodities. The record low orderbook coupled with upcoming environmental regulations that limit new vessel orders, also create favorable long term dynamics for our industry, which our Company is well positioned to enjoy.”



Recent Developments

Declaration of Dividend

  • The Company’s Board of Directors (the “Board”) declared a quarterly cash dividend of $0.30 per share on May 19, 2021, payable on or about June 14th, 2021 to all shareholders of record as of May 31st, 2021 (“Record Date”). The ex-dividend date is expected to be May 30th, 2021.

Updated Dividend Policy

  • In November 2019, the Board established a dividend policy, which is now updated, pursuant to which the Board intends to declare a dividend in each of February, May, August and November in an amount equal to (a) Star Bulk’s Total Cash Balance minus (b) the product of (i) the Minimum Cash Balance per Vessel and (ii) the Number of Vessels.
  • “Total Cash Balance” means (a) the aggregate amount of cash on Star Bulk’s balance sheet as of the last day of the quarter preceding the relevant dividend declaration date minus (b) any proceeds received by Star Bulk, including its subsidiaries, from vessel sales, or additional proceeds from vessel refinancings, or securities offerings in the last 12 months that have been earmarked for share repurchases, debt prepayment, vessel acquisitions and general corporate purposes.
  • “Minimum Cash Balance per Vessel” means:
    1. $1.40 million for March 31, 2021;
    2. $1.65 million for June 30, 2021
    3. $1.90 million for September 30, 2021
    4. $2.10 million for December 31, 2021 and thereafter
  • “Number of Vessels” means the total number of vessels owned by the Company, including its subsidiaries, or that are subject to sale and leaseback transactions and finance leases,  as of the last day of the quarter preceding the relevant dividend declaration date.
  • As of March 31, 2021, we owned 125 vessels and our Total Cash Balance was at $206.6 million. Adjusted for the Minimum Cash Balance per Vessel for March 31, 2021 of $1.40 million, resulted in total declared dividend amount of approximately $31.0 million or $0.30 per share.

Since Star Bulk is a holding company with no material assets other than the shares of its subsidiaries through which it conducts its operations, Star Bulk’s ability to pay dividends will depend on its subsidiaries distributing their earnings and cash flow to it. Any future dividends declared will be at the discretion and remain subject to approval of our Board each quarter, after its review of our financial condition and other factors, including but not limited to our earnings, prevailing charter market conditions, capital requirements, limitations under our debt agreements and applicable provisions of Marshall Islands law, which generally prohibits the payment of dividends other than from operating surplus or while a company is insolvent or would be rendered insolvent upon the payment of such dividend. Star Bulk’s dividend policy and declaration and payment of dividends may be changed at any time and are subject to legally available funds and the Board’s determination that each declaration and payment is at the time in the best interests of Star Bulk and its shareholders after its review of our financial performance. There can be no assurance that our Board will declare or pay any dividend in the future.  

Fleet Update:

On May 19, 2021 we took delivery of SBI Pegasus, the seventh and final vessel, pursuant to the previously announced transaction with ENETI INC (formerly known as Scorpio Bulkers Inc.). We issued to the relevant ENETI affiliates 350,797 common shares representing the share consideration for the seventh vessel and we assumed the outstanding lease obligations associated with the vessel. Following the issuance of these shares the Company has 102,239,716 common shares issued and outstanding.

COVID-19 and Our Proactive Measures

Despite the global gradual recovery from COVID-19, we continue to take proactive measures to ensure the health and wellness of our crew and onshore employees while maintaining effective business continuity and uninterrupted service to our customers. The overall impact of COVID-19 on our business, and the efficacy of any measures we take in response to the challenges presented by the COVID-19 pandemic, will depend on how the outbreak further develops, the duration and extent of the restrictive measures that are associated with the pandemic and their impact on global economy and trade, which is still uncertain.



Employment Overview



Daily Time Charter Equivalent Rate (“TCE”) and TCE Revenues are non-GAAP measures. Please see the table at the end of this release for a reconciliation to Voyage Revenues, which is the most directly comparable financial measure calculated and presented in accordance with U.S. GAAP, as well as for the definition of the respective measures.

*For the first quarter of 2021 our TCE rate was:

Capesize / Newcastlemax Vessels: $17,986 per day.
Post Panamax / Kamsarmax / Panamax Vessels: $14,791 per day.
Ultramax / Supramax Vessels: $13,632 per day.

Amounts shown throughout the press release and variations in period–on–period comparisons are derived from the actual unaudited numbers in our books and records. Reference to per share figures below are based on 99,019,944 and 95,916,480 weighted average diluted shares for the first quarter of 2021 and 2020, respectively.


First Quarter 2021 and 2020 Results

For the first quarter of 2021, we had a net income of $35.8 million, or $0.36 earnings per share. Net income for the first quarter of 2020 was $2.8 million, or $0.03 earnings per share.

Adjusted net income, which excludes certain non-cash items, was $35.7 million, or $0.36 earnings per share for the first quarter of 2021, compared to an adjusted net loss for the first quarter of 2020 of $22.3 million, or $0.23 loss per share.

Net cash provided by operating activities for the first quarter of 2021 was $79.2 million, compared to net cash provided by operating activities of $32.1 million for the first quarter of 2020. Adjusted EBITDA, which excludes certain non-cash items, was $84.7 million for the first quarter of 2021, compared to adjusted EBITDA of $32.6 million for the first quarter of 2020.

Voyage revenues for the first quarter of 2021 increased to $200.5 million from $160.9 million in the first quarter of 2020. Time charter equivalent revenues (“TCE Revenues”) (please see the table at the end of this release for the calculation of the TCE Revenues) were $156.4 million for the first quarter of 2021, compared to $99.8 million for the first quarter of 2020. TCE rate for the first quarter of 2021 was $15,461 compared to $10,949 for the first quarter of 2020.

For the first quarters of 2021 and 2020, vessel operating expenses were $47.4 million and $42.7 million, respectively. Vessel operating expenses for the first quarter of 2021 included pre-delivery and pre-joining expenses of $0.5 million and additional crew expenses related to the increased number of crew changes performed during the period as a result of COVID-19 restrictions imposed during 2020 of $1.3 million. Our average daily operating expenses per vessel for the first quarters of 2021 and 2020 were $4,410 and $4,047, respectively. Excluding non-recurring expenses such as pre-delivery and pre-joining expenses and the increased costs due to the COVID-19 pandemic in 2021, our average daily operating expenses per vessel for the first quarter of 2021 were $4,251.

General and administrative expenses for the first quarters of 2021 and 2020 were $7.3 million and $6.0 million, respectively. The increase is mainly attributable to the reversal, in the first quarter of 2020, of the previously recognized stock based compensation expense of $1.2 million following the reassessment of the probability of achieving the performance conditions for some of our outstanding awards. Vessel management fees for the first quarters of 2021 and 2020 were $4.7 million and $4.6 million, respectively. Our average daily net cash general and administrative expenses per vessel (including management fees and excluding stock-based compensation and other non-cash charges) for the first quarters of 2021 and 2020 were $1,087 and $1,064, respectively.

Interest and finance costs net of interest and other income/(loss) for the first quarters of 2021 and 2020 were $12.7 million and $20.1 million, respectively. Despite the increase in the weighted average balance of our outstanding indebtedness to $1,604.5 million during the first quarter of 2021, from $1,593.2 million for the same period in 2020, the interest and finance costs net of interest and other income/ (loss) decreased due to the decrease in the average interest rate on our outstanding indebtedness, mainly driven by the refinancing of certain of our debt agreements, the interest rate swap agreements that we entered into in 2020 and 2021 and the lower LIBOR rates during the first quarter of 2021 compared to the same period in 2020.


Unaudited Consolidated Statement of Operations

(Expressed in thousands of U.S. dollars except for share and per share data)   First quarter 2021


    First quarter 2020


   
           
           
Revenues:          
Voyage revenues   $ 200,467     $ 160,862    
Total revenues     200,467       160,862    
           
Expenses:          
Voyage expenses     (40,052 )     (55,310 )  
Charter-in hire expense     (2,943 )     (8,774 )  
Vessel operating expenses     (47,354 )     (42,718 )  
Dry docking expenses     (12,191 )     (13,361 )  
Depreciation     (36,233 )     (34,637 )  
Management fees     (4,667 )     (4,606 )  
General and administrative expenses     (7,297 )     (6,033 )  
Gain/(Loss) on forward freight agreements and bunker swaps     (2,085 )     27,586    
Other operational loss     (1,340 )     (51 )  
Other operational gain     1,017       477    
Gain on time charter agreement termination     1,102          
           
Operating income/(loss)     48,424       23,435    
           
Interest and finance costs     (14,440 )     (20,553 )  
Interest and other income/(loss)     1,750       447    
Loss on debt extinguishment           (542 )  
Total other expenses, net     (12,690 )     (20,648 )  
           
Income/(Loss) before equity in investee     35,734       2,787    
           
Equity in income/(loss) of investee     29       11    
           
Income/(Loss) before taxes   $ 35,763     $ 2,798    
           
Income taxes           (43 )  
           
Net income/(loss)   $ 35,763     $ 2,755    
           
Earnings/(loss) per share, basic and diluted   $ 0.36     $ 0.03    
Earnings/(loss) per share, diluted   $ 0.36     $ 0.03    
Weighted average number of shares outstanding, basic     98,712,581       95,797,142    
Weighted average number of shares outstanding, diluted     99,019,944       95,916,480    


Unaudited Consolidated Condensed Balance Sheet Data
 

(Expressed in thousands of U.S. dollars)  
   
ASSETS   March 31, 2021   December 31, 2020  
Cash and cash equivalents and resticted cash, current   $ 201,546     190,510  
Other current assets     139,395     116,901  
TOTAL CURRENT ASSETS     340,941     307,411  
           
Advances for vessels under construction and acquisition of vessels     11,012      
Vessels and other fixed assets, net     3,036,813     2,877,119  
Restricted cash, non current     5,021     5,021  
Other non-current assets     5,860     2,242  
TOTAL ASSETS   $ 3,399,647   $ 3,191,793  
           
Current portion of long-term bank loans and lease financing   $ 207,588   $ 189,773  
Other current liabilities     103,531     76,659  
TOTAL CURRENT LIABILITIES     311,119     266,432  
           
Long-term bank loans and lease financing non-current (net of unamortized
deferred finance fees of $19,007 and $19,942, respectively)
    1,383,750     1,321,116  
Senior Notes (net of unamortized deferred finance fees of $667 and $768,
respectively)
    49,333     49,232  
Other non-current liabilities     2,135     5,486  
TOTAL LIABILITIES   $ 1,746,337   $ 1,642,266  
           
SHAREHOLDERS’ EQUITY     1,653,310     1,549,527  
           
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY   $ 3,399,647   $ 3,191,793  



Unaudited Consolidated Condensed Cash Flow Data

(Expressed in thousands of U.S. dollars)   First quarter 2021


    First quarter 2020


   
                 
Net cash provided by / (used in) operating activities   $ 79,176     $ 32,097    
                 
  Vessel acquisitions and Advances for vessels under construction           (140,365 )        
  Capital expenditures for vessel modifications/upgrades     (11,395 )     (33,976 )  
  Insurance Proceeds         4,544       2,032    
Net cash provided by / (used in) investing activities     (147,216 )     (31,944 )  
                 
  Proceeds from vessels’ new debt     122,929       107,282    
  Scheduled vessels’ debt repayment     (43,416 )     (45,272 )  
  Debt prepayment due to sale or refinancing           (51,611 )  
  Financing fees         (1,340 )     (763 )  
  Refund of financing premia       903          
  Dividend payments               (4,749 )  
Net cash provided by / (used in) financing activities     79,076       4,887    



Summary of Selected Data

         
         
  First quarter 2021   First quarter 2020  
Average number of vessels (1)   119.3     116.0  
Number of vessels (2)   125     116  
Average age of operational fleet (in years) (3)   9.3     8.5  
Ownership days (4)   10,737     10,556  
Available days (5)   10,115     9,118  
Charter-in days (6)   175     367  
Daily Time Charter Equivalent Rate (7) $ 15,461   $ 10,949  
Average daily OPEX per vessel (8) $ 4,410   $ 4,047  
Average daily OPEX per vessel (excl. non recurring expenses) (8) $ 4,251   $ 4,047  
Average daily Net Cash G&A expenses per vessel (9) $ 1,087   $ 1,064  

(1) Average number of vessels is the number of vessels that constituted our owned fleet for the relevant period, as measured by the sum of the number of days each operating vessel was a part of our owned fleet during the period divided by the number of calendar days in that period.

(2) As of the last day of the periods reported.

(3) Average age of operational fleet is calculated as of the end of each period.

(4) Ownership days are the total calendar days each vessel in the fleet was owned by us
for the relevant period, including vessels subject to sale and leaseback transactions and finance leases.

(5) Available days for the fleet are the Ownership days after subtracting off-hire days for major repairs, dry docking or special or intermediate surveys and scrubber/Ballast Water Treatment System installation. The available days for the first quarter 2021, were also decreased by off-hire days relating to disruptions in connection with crew changes as a result of COVID-19. Our method of computing Available Days may not necessarily be comparable to Available Days of other companies due to differences in methods of calculation.

(6) Charter-in days are the total days that we charter-in vessels not owned by us.

(7) Time charter equivalent rate
represents the weighted average daily TCE rates of our operating fleet (including owned fleet and fleet under charter-in arrangements). TCE rate is a measure of the average daily net revenue performance of our vessels. Our method of calculating TCE rate is determined by dividing voyage revenues (net of voyage expenses, charter-in hire expense, amortization of fair value of above/below market acquired time charter agreements, if any, as well as adjusted for the impact of realized gain/(loss) on forward freight agreements (“FFAs”) and bunker swaps) by Available days for the relevant time period. Available days do not include the Charter-in days as per the relevant definitions provided above.
Voyage expenses primarily consist of port, canal and fuel costs that are unique to a particular voyage, which would otherwise be paid by the charterer under a time charter contract, as well as commissions. In the calculation of TCE Revenues, we also include the realized gain/(loss) on FFAs and bunker swaps as we believe that this method better reflects the chartering result of our fleet and is more comparable to the method used by our peers. TCE revenues and TCE rate, non-GAAP measures, provide additional meaningful information in conjunction with voyage revenues, the most directly comparable GAAP measure, because they assist our management in making decisions regarding the deployment and use of our vessels and because we believe that they provide useful information to investors regarding our financial performance. TCE rate is a standard shipping industry performance measure used primarily to compare period-to-period changes in a shipping company’s performance despite changes in the mix of charter types (i.e., voyage charters, time charters, bareboat charters and pool arrangements) under which its vessels may be employed between the periods. Our method of computing TCE may not necessarily be comparable to TCE of other companies due to differences in methods of calculation. For the detailed calculation please see the table at the end of this release with the reconciliation of Voyage Revenues to TCE.

(8) Average daily OPEX per vessel is calculated by dividing vessel operating expenses by Ownership days. Average daily OPEX per vessel (excluding non-recurring expenses) is calculated by dividing vessel operating expenses minus any non-recurring expenses (such as increased costs due to the COVID-19 pandemic or pre-delivery expenses for each vessel at acquisition, if any) by Ownership days. We exclude non-recurring expenses that may occur occasionally from our Average daily OPEX per vessel, since these generally represent items that we would not anticipate occurring as part of our normal business on a regular basis. We believe that Average daily OPEX per vessel (excluding non-recurring expenses) is a useful measure for our management and investors for period to period comparison with respect to our operating cost performance since such measure eliminates the effects of non-recurring items which may vary from period to period, are not part of our daily business and derive from reasons unrelated to overall operating performance. In the future we may incur expenses that are the same as or similar to some of the adjustments.

(9) Please see the table at the end of this release for the reconciliation to General and administrative expenses, the most directly comparable GAAP measure. We believe that Average daily Net Cash G&A expenses per vessel is a useful measure for our management and investors for period to period comparison with respect to our financial performance since such measure eliminates the effects of non-cash items which may vary from period to period, are not part of our daily business and derive from reasons unrelated to overall operating performance.


EBITDA and Adjusted EBITDA Reconciliation

We include EBITDA herein since it is a basis upon which we assess our liquidity position. It is also used by our lenders as a measure of our compliance with certain loan covenants and we believe that it presents useful information to investors regarding our ability to service and/or incur indebtedness.

To derive Adjusted EBITDA from EBITDA, we excluded non-cash gains/(losses) such as those related to sale of vessels, stock-based compensation expense, the write-off of the unamortized fair value of above/below market acquired time charters, impairment losses, loss from bad debt, change in fair value of forward freight agreements and bunker swaps and the equity in income/(loss) of investee and other non-cash charges, if any, which may vary from period to period and for different companies and because these items do not reflect operational cash inflows and outflows of our fleet.

EBITDA and Adjusted EBITDA do not represent and should not be considered as alternatives to cash flow from operating activities or net income, as determined by United States generally accepted accounting principles, or U.S. GAAP, and our calculation of EBITDA and Adjusted EBITDA may not be comparable to that reported by other companies due to differences in methods of calculation.

The following table reconciles net cash provided by operating activities to EBITDA and Adjusted EBITDA:

(Expressed in thousands of U.S. dollars)     First quarter 2021


    First quarter 2020


   
Net cash provided by/(used in) operating activities     $ 79,176     $ 32,097    
Net decrease / (increase)  in current assets       26,623       (1,391 )  
Net increase / (decrease) in operating  liabilities, excluding current
portion of long term debt
      (30,697 )     (16,497 )  
Loss on debt extinguishment             (542 )  
Stock – based compensation       (313 )     902    
Amortization of deferred finance charges       (1,815 )     (1,725 )  
Unrealized gain / (loss) on forward freight agreements and bunker
swaps
      (1,194 )     24,041    
Total other expenses, net       12,690       20,648    
Gain/(Loss) on hull and machinery claims             9    
Income tax             43    
Equity in income/(loss) of investee       29       11    
EBITDA     $ 84,499     $ 57,596    
             
Equity in (income)/loss of investee       (29 )     (11 )  
Gain on time charter agreement termination       (1,102 )        
Unrealized (gain)/loss on forward freight agreements and bunker
swaps
      1,194       (24,041 )  
Stock-based compensation       313       (902 )  
Other non-cash charges       (208 )     (77 )  
Adjusted EBITDA     $ 84,667     $ 32,565    

 


Net income/(Loss) and Adjusted Net income/(Loss) Reconciliation and calculation of Adjusted Earnings/(Loss) Per Share

To derive Adjusted Net Income and Adjusted Earnings/(Loss) Per Share from Net Income, we excluded non-cash items, as provided in the table below. We believe that Adjusted Net Income and Adjusted Earnings/(Loss) Per Share assist our management and investors by increasing the comparability of our performance from period to period since each such measure eliminates the effects of such non-cash items as gain/(loss) on sale of assets, unrealized gain/(loss) on derivatives, impairment losses and other items which may vary from year to year, for reasons unrelated to overall operating performance. In addition, we believe that the presentation of the respective measure provides investors with supplemental data relating to our results of operations, and therefore, with a more complete understanding of factors affecting our business than with GAAP measures alone. Our method of computing Adjusted Net Income and Adjusted Earnings/ (Loss) Per Share may not necessarily be comparable to other similarly titled captions of other companies due to differences in methods of calculation.

The following table reconciles Net income / (loss) to Adjusted Net income / (loss):

(Expressed in thousands of U.S. dollars except for share and per share data)   First quarter 2021


    First quarter 2020


   
Net income / (loss)   $ 35,763     $ 2,755    
Amortization of fair value of above/below market acquired time charter
agreements, net
    (187 )     (487 )  
Stock – based compensation     313       (902 )  
Other non-cash charges     (208 )     (77 )  
Unrealized (gain) / loss on forward freight agreements and bunker swaps     1,194       (24,041 )  
Loss on debt extinguishment           512    
Equity in income/(loss) of investee     (29 )     (11 )  
Gain on time charter agreement termination     (1,102 )        
Adjusted Net income / (loss)   $ 35,744     $ (22,251 )  
Weighted average number of shares outstanding, basic     98,712,581       95,797,142    
Weighted average number of shares outstanding, diluted     99,019,944       95,916,480    
Adjusted Earnings / (Loss) Per Share, basic and diluted   $ 0.36     $ (0.23 )  



Voyage Revenues to Daily Time Charter Equivalent (“TCE”) Reconciliation

(In thousands of U.S. Dollars, except for TCE rates)          
    First quarter 2021


    First quarter 2020


   
Voyage revenues   $ 200,467     $ 160,862    
Less:          
Voyage expenses     (40,052 )     (55,310 )  
Charter-in hire expense     (2,943 )     (8,774 )  
Realized gain/(loss) on FFAs/bunker swaps     (891 )     3,545    
Amortization of fair value of below/above market
acquired time charter agreements, net
    (187 )     (487 )  
Time Charter equivalent revenues   $ 156,394     $ 99,836    
           
Available days     10,115       9,118    
Daily Time Charter Equivalent Rate (“TCE”)   $ 15,461     $ 10,949    
           



Average daily Net Cash G&A expenses per vessel Reconciliation

(In thousands of U.S. Dollars, except for daily rates)            
    First quarter 2021


    First quarter 2020


   
General and administrative expenses   $ 7,297     $ 6,033    
Plus:            
Management fees     4,667       4,606    
Less:            
Stock – based compensation     (313 )     902    
Other non-cash charges     208       77    
Net Cash G&As expenses   $ 11,859     $ 11,618    
             
Ownership days     10,737       10,556    
Charter-in days     175       367    
Average daily Net Cash G&A expenses per vessel   $ 1,087     $ 1,064    

Conference Call details:
Our management team will host a conference call to discuss our financial results on Thursday, May 20, 2021 at 11:00 a.m., Eastern Time (ET).

Participants should dial into the call 10 minutes before the scheduled time using the following numbers: 1(877) 553-9962 (from the US), 0(808) 238-0669 (from the UK) or + (44) (0) 2071 928 592 (Standard International Dial In). Please quote “Star Bulk.”

A replay of the conference call will be available until Thursday, May 27, 2021. The United States replay number is 1(866) 331-1332; from the UK 0(808) 238-0667; the standard international replay number is (+44) (0) 3333 009 785 and the access code required for the replay is: 3128607#.

Slides and audio webcast:

There will also be a simultaneous live webcast over the Internet through the Star Bulk website (www.starbulk.com). Participants to the live webcast should register on the website approximately 10 minutes prior to the start of the webcast. The content on our website is not incorporated by reference into this release.

About Star Bulk

Star Bulk is a global shipping company providing worldwide seaborne transportation solutions in the dry bulk sector. Star Bulk’s vessels transport major bulks, which include iron ore, minerals and grain, and minor bulks, which include bauxite, fertilizers and steel products. Star Bulk was incorporated in the Marshall Islands on December 13, 2006 and maintains executive offices in Athens, Oslo, New York, Limassol and Singapore. Its common stock trades on the Nasdaq Global Select Market under the symbol “SBLK”. Star Bulk will operate on a fully delivered basis a fleet of 128 vessels, with an aggregate capacity of 14.1 million dwt, consisting of 17 Newcastlemax, 22 Capesize, 2 Mini Capesize, 7 Post Panamax, 41 Kamsarmax, 2 Panamax, 20 Ultramax and 17 Supramax vessels with carrying capacities between 52,425 dwt and 209,537 dwt.

Forward-Looking Statements

Matters discussed in this press release may constitute forward looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts.

We desire to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. Words such as, but not limited to, “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “targets,” “projects,” “likely,” “would,” “could,” “should,” “may,” “forecasts,” “potential,” “continue,” “possible” and similar expressions or phrases may identify forward-looking statements.

The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, examination by our management of historical operating trends, data contained in our records and other data available from third parties. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that we will achieve or accomplish these expectations, beliefs or projections.

In addition to these important factors, other important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include general dry bulk shipping market conditions, including fluctuations in charter rates and vessel values; the strength of world economies; the stability of Europe and the Euro; fluctuations in interest rates and foreign exchange rates; the impact of the expected discontinuance of the London Interbank Offered Rate, or LIBOR, after 2021 on interest rates of our debt that reference LIBOR; business disruptions due to natural disasters or other disasters outside our control, such as the ongoing global outbreak of the novel coronavirus (“COVID-19”); the length and severity of epidemics and pandemics, including COVID-19 and its impact on the demand for seaborne transportation in the dry bulk sector; changes in supply and demand in the dry bulk shipping industry, including the market for our vessels and the number of newbuildings under construction; the potential for technological innovation in the sector in which we operate and any corresponding reduction in the value of our vessels or the charter income derived therefrom; changes in our operating expenses, including bunker prices, dry docking, crewing and insurance costs; changes in governmental rules and regulations or actions taken by regulatory authorities; potential liability from pending or future litigation and potential costs due to environmental damage and vessel collisions; the impact of increasing scrutiny and changing expectations from investors, lenders, charterers and other market participants with respect to our Environmental, Social and Governance (“ESG”) policies; general domestic and international political conditions or events, including “trade wars”; the impact on our common shares and reputation if our vessels were to call on ports located in countries that are subject to restrictions imposed by the U.S. or other governments; potential disruption of shipping routes due to accidents or political events; the availability of financing and refinancing; the failure of our contract counterparties to meet their obligations; our ability to meet requirements for additional capital and financing to grow our business; the impact of our indebtedness and the compliance with the covenants included in our debt agreements; vessel breakdowns and instances of off‐hire; potential exposure or loss from investment in derivative instruments; potential conflicts of interest involving our Chief Executive Officer, his family and other members of our senior management and our ability to complete acquisition transactions as and when planned. Please see our filings with the Securities and Exchange Commission for a more complete discussion of these and other risks and uncertainties. The information set forth herein speaks only as of the date hereof, and the Company disclaims any intention or obligation to update any forward‐looking statements as a result of developments occurring after the date of this communication.

Contacts

Company:

Simos Spyrou, Christos Begleris
Co ‐ Chief Financial Officers
Star Bulk Carriers Corp.
c/o Star Bulk Management Inc.
40 Ag. Konstantinou Av.
Maroussi 15124
Athens, Greece
Email: [email protected]
www.starbulk.com

Investor Relations / Financial Media:

Nicolas Bornozis
President
Capital Link, Inc.
230 Park Avenue, Suite 1536
New York, NY 10169
Tel. (212) 661‐7566
E‐mail: [email protected]
www.capitallink.com